The stock of TC BioPharm (Holdings) plc ADR (TCBP) has seen a -20.26% decrease in the past week, with a -39.30% drop in the past month, and a -82.38% decrease in the past quarter. The volatility ratio for the week is 11.80%, and the volatility levels for the past 30 days are at 17.33% for TCBP. The simple moving average for the past 20 days is -27.37% for TCBP’s stock, with a -93.59% simple moving average for the past 200 days.
Is It Worth Investing in TC BioPharm (Holdings) plc ADR (NASDAQ: TCBP) Right Now?
Additionally, the 36-month beta value for TCBP is -0.16. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The average trading volume of TCBP on January 23, 2025 was 2.13M shares.
TCBP) stock’s latest price update
TC BioPharm (Holdings) plc ADR (NASDAQ: TCBP) has experienced a decline in its stock price by -11.38 compared to its previous closing price of 0.36. However, the company has seen a fall of -20.26% in its stock price over the last five trading days. prnewswire.com reported 2025-01-15 that EDINBURGH, Scotland, Jan. 15, 2025 /PRNewswire/ — TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it intends to begin Proof of Concept preclinical studies for its lead therapeutic TCB008, for treatment in H5N1, commonly known as “Bird Flu.” The Company is currently approaching potential university partners to expedite the preclinical work required for a Phase I study.
TCBP Trading at -35.81% from the 50-Day Moving Average
After a stumble in the market that brought TCBP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.78% of loss for the given period.
Volatility was left at 17.33%, however, over the last 30 days, the volatility rate increased by 11.80%, as shares sank -42.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -67.03% lower at present.
During the last 5 trading sessions, TCBP fell by -23.75%, which changed the moving average for the period of 200-days by -97.99% in comparison to the 20-day moving average, which settled at $0.4399. In addition, TC BioPharm (Holdings) plc ADR saw -37.98% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for TCBP
The total capital return value is set at -3.6.
Based on TC BioPharm (Holdings) plc ADR (TCBP), the company’s capital structure generated 0.45 points at debt to capital in total, while cash flow to debt ratio is standing at -5.52.
Currently, EBITDA for the company is -13.61 million with net debt to EBITDA at -0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.79.
Conclusion
In conclusion, TC BioPharm (Holdings) plc ADR (TCBP) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
